Use of lecanemab for the treatment of Alzheimer's disease: A systematic review
Brain and Behavior · 2024-06 · 14 (6)
DOI: 10.1002/brb3.3592 ↗At a glance
Systematische Übersicht in Brain and Behavior, published online on 2024-06-12. Written by Md Fahad Hossain and 2 co-authors. Institution: Ministry of Health and Family Welfare, Dhaka, Bangladesh. Major MEDLINE topics: Alzheimer Disease, Antibodies, Monoclonal, Humanized. Cited 16 times so far (Crossref); 30 references. The full text is freely available (open access, CC BY 4.0).
Topics: Demenz
Abstract (original language)
Purpose
The US Food and Drug Administration authorized lecanemab for the therapeutic use of Alzheimer's disease (AD) in January 2023. To assess the effectiveness and safety of lecanemab in treating AD, we thoroughly examined the studies that are currently accessible.
Method
Preferred Reporting Items for Systematic Reviews and Meta‐Analysis recommendations were followed. In order to find relevant studies on lecanemab, we carried out a thorough literature search utilizing the electronic databases MEDLINE via PubMed, Cochrane, Web of Science, EBSCOhost, and Scopus. Excluding any research using experimental animals, we looked at lecanemab's effectiveness and side effects in treating AD in human clinical trials. Three randomized controlled studies were included.
Findings
According to studies, lecanemab lessens clinical deterioration and reduces brain amyloid‐beta plaques (difference,.45; 95% confidence interval,.67 to.23; p < .001). Participants who received lecanemab saw a greater frequency of amyloid‐related imaging abnormalities (ARIA)‐H (17.3% vs. 9.0%) and ARIA‐E (12.6% vs. 1.7%), which is a significant adverse outcome.
Conclusion
Lecanemab has been shown to have an impact on the two primary pathophysiologic indicators of AD (Aβ and tau). There are still a lot of unresolved issues related to lecanemab. Future research on the effectiveness and safety of lecanemab is advised in order to determine that the advantages of this medication exceed the disadvantages.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Ministry of Health and Family Welfare, Dhaka, Bangladesh.
- Mercy Health St. Elizabeth Youngstown Hospital, Youngstown, Ohio, USA.
- Department of Medicine, Kathmandu Medical College, Kathmandu, Nepal.
ORCID profiles: Md Fahad Hossain
Cite
APA
Hossain, M. F., Husna, A. U., & Kharel, M. (2024). Use of lecanemab for the treatment of Alzheimer's disease: A systematic review. Brain and Behavior, 14(6). https://doi.org/10.1002/brb3.3592
Vancouver
Hossain MF, Husna AU, Kharel M. Use of lecanemab for the treatment of Alzheimer's disease: A systematic review. Brain and Behavior. 2024;14(6). doi:10.1002/brb3.3592
BibTeX
@article{Hossain2024,
author = {Hossain, Md Fahad and Husna, Ashma Ul and Kharel, Manish},
title = {Use of lecanemab for the treatment of Alzheimer's disease: A systematic review},
journal = {Brain and Behavior},
year = {2024},
volume = {14},
number = {6},
doi = {10.1002/brb3.3592}
}
EUVIMED